POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%

Clinical safety rating: safe

No significant drug interactions Can cause hypernatremia and fluid overload.

How it works

Potassium is the principal intracellular cation; it corrects hypokalemia and maintains cellular membrane potential. Sodium chloride provides sodium and chloride ions to maintain fluid balance and osmolarity.

What the body does with it

Metabolism	Potassium is primarily eliminated by the kidneys; not metabolized. Sodium chloride is distributed and excreted unchanged.
Excretion	Renal: >90% of administered potassium is excreted by the kidneys, primarily via distal tubular secretion in the collecting duct. Fecal: <10% eliminated in feces. Biliary: negligible.
Half-life	Not applicable as potassium is an electrolyte; its serum half-life depends on redistribution and renal function. In normal renal function, excess exogenous potassium is eliminated within hours; terminal elimination half-life is approximately 2-4 hours in healthy individuals but prolonged in renal impairment.
Protein binding	Not significantly bound to plasma proteins; essentially 0% bound.
Volume of Distribution	Approximately 0.5-0.7 L/kg total body water; distributes throughout extracellular and intracellular compartments. Clinical meaning: rapid distribution into the intracellular space; Vd approximates total body water.
Bioavailability	Intravenous: 100% (directly into bloodstream). Oral: 90-100% (well absorbed from the gastrointestinal tract, primarily in the small intestine).
Onset of Action	Intravenous infusion: Immediate (within seconds to minutes) effect on serum potassium levels; clinical effect on cardiac conduction (ECG changes) seen within minutes. Oral: onset of action is delayed (1-2 hours) for absorption and redistribution.
Duration of Action	Intravenous: Duration depends on rate of infusion and renal elimination; effect lasts as long as infusion continues. After cessation, serum potassium returns to baseline within hours. Oral: duration of effect is 4-6 hours for maintenance therapy; sustained-release formulations extend duration.

Classification & Brands

Dosing & administration

Intravenous infusion: Typically 10-20 mEq/h (max 40 mEq/h) with continuous ECG monitoring; rate not to exceed 1 mEq/min. Concentration: 0.15% KCl in 0.45% NaCl provides 2 mEq KCl per 100 mL. Administer via central line if concentration > 0.1%.

Dosage form	INJECTABLE
Renal impairment	GFR > 50 mL/min: No adjustment. GFR 30-50 mL/min: Reduce dose by 25% and monitor potassium closely. GFR < 30 mL/min: Avoid use unless severe hypokalemia and dialysis available; use with extreme caution, reduce dose by 50% and monitor ECG/serum K+ frequently.
Liver impairment	Child-Pugh A: No adjustment. Child-Pugh B: Reduce initial dose by 25% and titrate based on potassium levels. Child-Pugh C: Avoid use if possible; if necessary, reduce dose by 50% and monitor potassium and ECG closely due to risk of hyperkalemia.
Pediatric use	Intravenous infusion: 0.5-1 mEq/kg/dose, max 40 mEq/dose; rate not to exceed 0.5-1 mEq/kg/h under continuous ECG monitoring. Use with 0.45% sodium chloride; maximum infusion rate 0.5 mEq/kg/h.
Geriatric use	Start at lower end of dosing range (e.g., 5-10 mEq/h) due to age-related decline in renal function and increased risk of hyperkalemia. Monitor serum potassium and renal function frequently. Avoid rapid infusion rates.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

No significant drug interactions Can cause hypernatremia and fluid overload.

FDA category	Animal
Breastfeeding	Potassium and sodium are normal constituents of breast milk. No specific M/P ratio known; supplementation at therapeutic doses is considered compatible with breastfeeding.
Teratogenic Risk	Potassium chloride and sodium chloride are physiological ions; no teratogenic risk is expected at therapeutic doses. Trimester-specific risks: no known fetal harm from electrolyte replacement.

Warnings & precautions

■ FDA Black Box Warning

None.

Side Effect Profile

Common Effects	fluid replacement
Serious Effects

Absolute Contraindications

["Hyperkalemia","Severe renal impairment with oliguria or anuria","Addison's disease","Acute dehydration","Concomitant use with potassium-sparing diuretics"]

Clinical Precautions

Precautions

["Monitor serum potassium levels frequently to avoid hyperkalemia","Risk of hyperkalemia in patients with renal impairment, diabetes, or conditions causing tissue breakdown","Use with caution in patients with cardiac disease or receiving digitalis","Rate of infusion should not exceed 10 mEq/hour; concentration should not exceed 40 mEq/L"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%

Clinical safety rating: safe

No significant drug interactions Can cause hypernatremia and fluid overload.

How it works

What the body does with it

Metabolism	Potassium is primarily eliminated by the kidneys; not metabolized. Sodium chloride is distributed and excreted unchanged.
Excretion	Renal: >90% of administered potassium is excreted by the kidneys, primarily via distal tubular secretion in the collecting duct. Fecal: <10% eliminated in feces. Biliary: negligible.
Half-life	Not applicable as potassium is an electrolyte; its serum half-life depends on redistribution and renal function. In normal renal function, excess exogenous potassium is eliminated within hours; terminal elimination half-life is approximately 2-4 hours in healthy individuals but prolonged in renal impairment.
Protein binding	Not significantly bound to plasma proteins; essentially 0% bound.
Volume of Distribution	Approximately 0.5-0.7 L/kg total body water; distributes throughout extracellular and intracellular compartments. Clinical meaning: rapid distribution into the intracellular space; Vd approximates total body water.
Bioavailability	Intravenous: 100% (directly into bloodstream). Oral: 90-100% (well absorbed from the gastrointestinal tract, primarily in the small intestine).
Onset of Action	Intravenous infusion: Immediate (within seconds to minutes) effect on serum potassium levels; clinical effect on cardiac conduction (ECG changes) seen within minutes. Oral: onset of action is delayed (1-2 hours) for absorption and redistribution.
Duration of Action	Intravenous: Duration depends on rate of infusion and renal elimination; effect lasts as long as infusion continues. After cessation, serum potassium returns to baseline within hours. Oral: duration of effect is 4-6 hours for maintenance therapy; sustained-release formulations extend duration.

Classification & Brands

Dosing & administration

Dosage form	INJECTABLE
Renal impairment	GFR > 50 mL/min: No adjustment. GFR 30-50 mL/min: Reduce dose by 25% and monitor potassium closely. GFR < 30 mL/min: Avoid use unless severe hypokalemia and dialysis available; use with extreme caution, reduce dose by 50% and monitor ECG/serum K+ frequently.
Liver impairment	Child-Pugh A: No adjustment. Child-Pugh B: Reduce initial dose by 25% and titrate based on potassium levels. Child-Pugh C: Avoid use if possible; if necessary, reduce dose by 50% and monitor potassium and ECG closely due to risk of hyperkalemia.
Pediatric use	Intravenous infusion: 0.5-1 mEq/kg/dose, max 40 mEq/dose; rate not to exceed 0.5-1 mEq/kg/h under continuous ECG monitoring. Use with 0.45% sodium chloride; maximum infusion rate 0.5 mEq/kg/h.
Geriatric use	Start at lower end of dosing range (e.g., 5-10 mEq/h) due to age-related decline in renal function and increased risk of hyperkalemia. Monitor serum potassium and renal function frequently. Avoid rapid infusion rates.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

No significant drug interactions Can cause hypernatremia and fluid overload.

FDA category	Animal
Breastfeeding	Potassium and sodium are normal constituents of breast milk. No specific M/P ratio known; supplementation at therapeutic doses is considered compatible with breastfeeding.
Teratogenic Risk	Potassium chloride and sodium chloride are physiological ions; no teratogenic risk is expected at therapeutic doses. Trimester-specific risks: no known fetal harm from electrolyte replacement.

Warnings & precautions

■ FDA Black Box Warning

None.

Side Effect Profile

Common Effects	fluid replacement
Serious Effects

Absolute Contraindications

["Hyperkalemia","Severe renal impairment with oliguria or anuria","Addison's disease","Acute dehydration","Concomitant use with potassium-sparing diuretics"]